- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Grantham Mayo Van Otterloo & Co. LLC Increases Bristol Myers Squibb Holdings
Investment firm boosts stake in pharmaceutical company by 11.2% in Q3
Published on Mar. 8, 2026
Got story updates? Submit your updates here. ›
Grantham Mayo Van Otterloo & Co. LLC, a prominent investment management firm, increased its position in Bristol Myers Squibb Company (NYSE:BMY) by 11.2% during the third quarter of the year. The firm now owns 967,975 shares of the biopharmaceutical company's stock, valued at $43.66 million.
Why it matters
This move by Grantham Mayo Van Otterloo & Co. LLC, a respected institutional investor, signals their confidence in Bristol Myers Squibb's long-term growth potential. As a major shareholder, their increased stake could influence the company's strategic direction and investor sentiment.
The details
According to the company's most recent SEC filing, Grantham Mayo Van Otterloo & Co. LLC purchased an additional 97,671 shares of Bristol Myers Squibb during the third quarter. This brings their total holdings in the biopharmaceutical firm to nearly 1 million shares, making them a significant institutional investor in the company.
- Grantham Mayo Van Otterloo & Co. LLC increased its Bristol Myers Squibb holdings during the 3rd quarter of 2026.
The players
Grantham Mayo Van Otterloo & Co. LLC
A prominent investment management firm that has increased its stake in Bristol Myers Squibb Company.
Bristol Myers Squibb Company
A global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases.
The takeaway
Grantham Mayo Van Otterloo & Co. LLC's increased investment in Bristol Myers Squibb suggests the firm sees strong growth potential in the biopharmaceutical company. This move could signal positive sentiment among institutional investors towards Bristol Myers Squibb's future prospects.
